WebAccording to the positive results of HIMALAYA trial , cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitor tremelimumab plus programmed death ligand-1 (PD-L1) inhibitor durvalumab is recommended as an alternative first-line therapy to Atezo-Bev by the BCLC group, while durvalumab monotherapy is approved in the first-line setting by the … Web28 mar 2024 · The combination of atezolizumab and bevacizumab is currently the preferred first-line therapy in patients not at risk of bleeding. Additionally, the HIMALAYA trial has demonstrated the superiority of the durvalumab plus tremelimumab combination (STRIDE regimen) therapy in efficacy and safety compared with sorafenib in patients with …
Imfinzi and tremelimumab granted Orphan Drug Designation …
Web29 mag 2024 · Results from the global Phase II Study 22 trial testing AstraZeneca’s tremelimumab, an anti-CTLA4 antibody, added to Imfinzi (durvalumab) demonstrated promising clinical activity and tolerability in patients with advanced hepatocellular carcinoma (HCC). HCC is the most common type of liver cancer. 1 In the primary endpoint of the … Web2 ott 2024 · Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA) The safety and scientific validity … lavington newsagency
Durvalumab Plus Chemo Significantly Improves OS in Frontline …
Web25 apr 2024 · HIMALAYA was a randomised, open-label, multicentre, global Phase III trial of Imfinzi monotherapy and the STRIDE regimen, comprising a single priming dose of … Web25 ott 2024 · “We have now delivered 2 positive gastrointestinal cancer trials in a row for [durvalumab], following the HIMALAYA trial [NCT03298451] in liver cancer. Web13 giu 2024 · Other ongoing phase III trials investigating pembrolizumab-based regimens in HCC that may inform treatment selection in various settings include KEYNOTE-937 of pembrolizumab as adjuvant therapy (NCT03867084), and LEAP-012 of the combination of pembrolizumab and lenvatinib, in combination with transarterial chemoembolization for … k12 strong workforce